- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01006421
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo (GB)
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial
Vitiligo is a common chronic skin disease with 1-4% prevalence. It has a significant psychosocial impact on patients and society. Different treatment modalities with variable success rates are available.
Phototherapy is among the successful treatments but gives modest results. Some reports documented the usefulness of Ginkgo Biloba (GB) when used alone in Vitiligo treatment.
Study Overview
Detailed Description
Adding GB to phototherapy, especially the most commonly used one; Narrow-Band UVB (NBUVB) might give better results than using either one alone. This might improve repigmentation as well as patients' quality-of-life. (QOL).
This will be a prospective double-blind randomized controlled clinical trial. One-hundred-sixty Vitiligo patients will be randomly divided into 2 groups( 80 patients per group).
One group will receive oral GB (2 tablets of 60 mgs twice daily) with NBUVB twice weekly.
The other group will receive placebo tablets( identical in size, shape and color) to GB twice daily with NBUVB twice weekly.
Both groups will be treated for 6 months. Standard protocol of phototherapy will be used for both groups.
Our aim here is to see whether adding GB to NBUVB will lead to better repigmentation than placebo or not.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: KHALID M ALGHAMDI, MD
- Phone Number: 4690815
- Email: kmgderm@yahoo.com
Study Locations
-
-
Central
-
Riyadh, Central, Saudi Arabia
- Recruiting
- King Khalid University Hospital
-
Contact:
- KHALID M ALGHAMDI, MD
- Phone Number: 4690815
- Email: kmgderm@yahoo.com
-
Principal Investigator:
- KHALID M ALGHAMDI, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any Vitiligo patient (age 12 years and above) with non-segmental Vitiligo.
- Body surface area (BSA) involvement ≥ 3%.
Exclusion Criteria:
- Unable to consent
- Any topical, systemic or phototherapy for Vitiligo in the previous 2 months.
- Pregnancy, breast feeding.
- Liver or kidney disease.
- Epilepsy
- Bleeding disorder or anticoagulant treatment
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Repigmentation (more than 50% from baseline) as the primary outcome
Time Frame: 3,6 and 9 months
|
3,6 and 9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality-of-life - as secondary outcome .
Time Frame: 3,6 and 9 months
|
3,6 and 9 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: KHALID M ALGHAMDI, MD, KSU
Study record dates
Study Major Dates
Study Start
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GB-NBVUB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on GINGKO BILOBA
-
Robert Ritch, MD, LLC.UnknownNormal Tension GlaucomaUnited States
-
Boehringer IngelheimCompleted
-
State University of New York College of OptometryCompleted
-
National Center for Complementary and Integrative...CompletedIntermittent Claudication | Peripheral Vascular DiseaseUnited States
-
National Center for Complementary and Integrative...Completed
-
National Institutes of Health Clinical Center (CC)Completed
-
Bagcilar Training and Research HospitalCompleted
-
EMSWithdrawn
-
VSM Geneesmiddelen b.v.CompletedRaynaud DiseaseNetherlands